GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Pricing authority caps rates of key diabetes drugs
India's drug pricing authority has brought two key anti-diabetic drugs - Sitagliptin-Metformin combination and Linagliptin-Metformin combination - under price control. For a 2.5 mg Linagliptin-metformin tablet, the price has been fixed at 16.17, and for the same combination in 5 mg strength, the price will be 25.33 per tablet. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 25, 2022 Category: Pharmaceuticals Source Type: news

EU Green Light for Finerenone for CKD, Growth Hormone for Kids EU Green Light for Finerenone for CKD, Growth Hormone for Kids
Positive opinions issued for branded somatrogon and finerenone and for generic versions of sitagliptin/metformin hydrochloride and sapropterin.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 20, 2021 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news

New studies show diabetes drug not proven to improve blood sugar control in pediatric patients
The FDA has approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in pediatric patients. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

metformin and sitagliptin (Janumet)
Title: metformin and sitagliptin (Janumet)Category: MedicationsCreated: 7/28/2010 12:00:00 AMLast Editorial Review: 7/3/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - July 3, 2019 Category: Endocrinology Source Type: news

Oral Semaglutide Tops Sitagliptin for Cutting HbA1c, Weight in T2D
(MedPage Today) -- Positive results from PIONEER 3 trial in diabetic patients who aren ' t responding to metformin with or without sulfonylurea (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 24, 2019 Category: Cardiology Source Type: news

Metformin vs. Janumet
Title: Metformin vs. JanumetCategory: MedicationsCreated: 12/21/2018 12:00:00 AMLast Editorial Review: 12/21/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 21, 2018 Category: Drugs & Pharmacology Source Type: news

Domestic pharma retail market grows 13% in July
Anti-diabetic therapy dominated the pecking order with four of the top 10 brands, Galvus MET and Janumet being the other top grossers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 16, 2018 Category: Pharmaceuticals Source Type: news

Sitagliptin-Metformin Therapy in Prior Gestational Diabetics Sitagliptin-Metformin Therapy in Prior Gestational Diabetics
Find out about the benefits treatment with sitagliptin combined with metformin may provide prediabetic women with a history of gestational diabetes.Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk How to find good candidates? Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed. To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news

Ertugliflozin: Promise From Yet Another SGLT-2 Inhibitor (CME/CE)
(MedPage Today) -- Assessed as triple agent therapy when added to metformin, sitagliptin (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 25, 2017 Category: Cardiology Source Type: news

Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials
In two phase 3 trials, the SGLT2 inhibitor ertugliflozin for the treatment of type 2 diabetes that is uncontrolled with metformin alone or with sitagliptin demonstrated safety and efficacy at 52 weeks.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Janumet (Sitagliptin Metformin HCL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 28, 2017 Category: Drugs & Pharmacology Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck ’s Supplemental New Drug Applications for JANUVIA®(sitagliptin), JANUMET® (sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin and metformin HCl extended-release).Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExcha...
Source: Merck.com - Corporate News - April 7, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Janumet XR (Sitagliptin and Metformin HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2017 Category: Drugs & Pharmacology Source Type: news